|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane显示文摘 | Buzdar AU Robertson JF Eiermann W | 2002 | Cancer2002，95，9： | 1 |
| 2 | Mulficenter phase 11 study of capecitabine in paclitaxel-refractory metastatic breast cancer显示文摘 | Blum JL Jones SE Buzdar AU | 1999 | J Clin Oncol1999，17，： | 1 |
| 3 | Inflammatory breast cancer:a veiew显示文摘 | Jaiyesimi IA Buzdar AU Hartobagyi G | | 0，，： | 1 |
| 4 | Anastrozole alone or in combina-tion with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC(Arimidex,Tamoxifen Alone or in Combination)trial efficacy and safety update analyses显示文摘 | Baum M Buzdar A Cuzick J | 2003 | Cancer2003，98，9： | 1 |
| 5 | Evolving novel anti-HER2 strategies显示文摘 | Jones KL Buzdar AU | 2009 | Lancet Oncol2009，10，12： | 1 |
| 6 | Breast carcinoma in men: a population-based study 显示文摘 | Giordano S H Cohen DS Buzdar A U | 2004 | Cancer2004，101，1： | 1 |
| 7 | Breast carcinoma in men:a population-based study显示文摘 | Giordano SH Cohen DS Buzdar AU | 2004 | Cancer2004，101，1： | 1 |
| 8 | Breast carcinoma in men : a population-based study显示文摘 | Giordano SH Cohen DS Buzdar AU | 2004 | Cancer2004，101，1： | 1 |
| 9 | Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab,paclitaxel,and epirubicin chemotherapy:results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer显示文摘 | Buzdar A Ibrahim N Francis D | 2005 | J Clin Oncol2005，23，16： | 1 |
| 10 | Prospective evaluation of paclitaxe versus combination chemotherapy with fluorouracil,doxorubicin and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer显示文摘 | Buzdar AU Singletary SE Theriault RL | 1999 | J Clin Oncol1999，17，11： | 1 |
| 11 | Static disease on anastrozel provides similar benefit as objective response in patients with advance breast cancer 显示文摘 | Howell A Buzdar A Robertson J | 1999 | Breast Cancer Res Treat1999，58，2： | 1 |
| 12 | Breast cancer in men显示文摘 | Giordano SH Buzdar AU Hortobagyi GN | 2002 | Ann Intern Med2002，137，8： | 1 |
| 13 | Phase Ⅱ trial of liposome-encapsulated doxorubicin,cyclophosphamide,and fluorouracil as first-line therapy in patients with metastatic breast cancer显示文摘 | Buzdar AU Theriault RL | 1999 | J Clin Oncol1999，17，5： | 1 |
| 14 | Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab,paclitaxel,and epirubicin chemotherapy:results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer显示文摘 | Buzdar AU Ibrahim NK Francis D | 2005 | J Clin Onco12005，23，16： | 1 |
| 15 | Residual metastatic axil-lary lymph nodes following neoadjuvant chemotherapy predict dis-ease-free survival in patients with locally advanced breast cancer 显示文摘 | Kuerer HM Newman LA Buzdar AU | 1998 | Am J Surg1998，176，6： | 1 |
| 16 | Multieenter phaseⅡstudy of eapecitabine in paclitaxel-refractory metastatic breast cancer显示文摘 | Blum JL Jones SK Buzdar A12 | 2009 | Clin Oncol2009，17，2： | 1 |
| 17 | Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative 'Arimidex' Compared to Tamoxifen (PROACT) trial 显示文摘 | Cataliotti L Buzdar AU Noguchi S | 2006 | Cancer2006，106，10： | 1 |
| 18 | Phase Ⅲ randomized trial of droloxifene and tomoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer 显示文摘 | Buzdar A Hayes D El-Khoudaary A | 2002 | Breast Cancer Research and Treatment2002，73，： | 1 |
| 19 | Evolving novel anti-HER2 strategies显示文摘 | Jones KL Buzdar AU | 2009 | Lancet Oneol2009，10，12： | 1 |
| 20 | Chemotherapy-induced peripheral neuropathy as a predictor of neuropathic pain in breast cancer patients previously treated with paclitaxel显示文摘 | Reyes-Gibby CC Morrow PK Buzdar A | 2009 | J Pain2009，10，11： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员